- Home
- USIO vs ADVM Comparison
USIO vs ADVM Comparison
Compare USIO & ADVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USIO
- ADVM
- Stock Information
- Founded
- USIO 1998
- ADVM 2006
- Country
- USIO United States
- ADVM United States
- Employees
- USIO N/A
- ADVM N/A
- Industry
- USIO Investment Bankers/Brokers/Service
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- USIO Finance
- ADVM Health Care
- Exchange
- USIO Nasdaq
- ADVM Nasdaq
- Market Cap
- USIO 50.2M
- ADVM 49.9M
- IPO Year
- USIO N/A
- ADVM 2014
- Fundamental
- Price
- USIO $1.52
- ADVM $2.86
- Analyst Decision
- USIO Strong Buy
- ADVM Strong Buy
- Analyst Count
- USIO 1
- ADVM 4
- Target Price
- USIO $4.00
- ADVM $19.75
- AVG Volume (30 Days)
- USIO 104.3K
- ADVM 111.1K
- Earning Date
- USIO 08-06-2025
- ADVM 08-12-2025
- Dividend Yield
- USIO N/A
- ADVM N/A
- EPS Growth
- USIO N/A
- ADVM N/A
- EPS
- USIO 0.11
- ADVM N/A
- Revenue
- USIO $83,851,606.00
- ADVM $1,000,000.00
- Revenue This Year
- USIO $16.02
- ADVM N/A
- Revenue Next Year
- USIO $13.24
- ADVM $18.82
- P/E Ratio
- USIO $14.21
- ADVM N/A
- Revenue Growth
- USIO 2.05
- ADVM N/A
- 52 Week Low
- USIO $1.24
- ADVM $1.78
- 52 Week High
- USIO $2.92
- ADVM $8.56
- Technical
- Relative Strength Index (RSI)
- USIO 42.47
- ADVM 61.84
- Support Level
- USIO $1.38
- ADVM $2.20
- Resistance Level
- USIO $2.02
- ADVM $2.57
- Average True Range (ATR)
- USIO 0.13
- ADVM 0.21
- MACD
- USIO -0.03
- ADVM 0.04
- Stochastic Oscillator
- USIO 21.87
- ADVM 95.65
About USIO Usio Inc.
Usio Inc is a United States-based company that provides integrated electronic payment services, including credit and debit card-based processing services and transaction processing via the Automated Clearing House, or ACH network to billers and retailers. The Company also has an additional wholly-owned subsidiary, which is the entity for Output Solutions operations.
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.